The brain doesn’t forgive shortcuts. It doesn’t hand out mulligans to companies chasing shiny objects. Which is why what just went down in Worcester deserves a double take. Leal Therapeutics, founded by Asa Abeliovich, M.D., Ph.D., just locked in a $30M Series A led by SV Health Investors’ Dementia Discovery Fund, with OrbiMed, Newpath Partners, Chugai Venture Fund, Euclidean Capital, Alexandria Venture Investments, and PhiFund all doubling down. Add in the $39M seed and the $45M follow-on in 2024, and you’re staring at $114M behind a team rewriting the playbook on how to treat central nervous system disorders.
Leal Therapeutics isn’t slinging symptom band-aids. They’re correcting the metabolic misfires inside the brain that drive diseases most companies have long abandoned. Their lead candidate LTX-001 is an oral small molecule going straight at glutaminase, dialing down runaway glutamate in schizophrenia, bipolar disorder, major depression, and ALS. LTX-002 is an antisense oligonucleotide targeting SPTLC1, stopping toxic lipid buildup before it strangles neurons in ALS. And LTX-007 is aimed at sphingolipid dysfunction in Alzheimer’s and rare sphingolipidoses. These aren’t cautious shots on goal; they’re calculated swings at some of medicine’s toughest walls.
Asa Abeliovich isn’t new to this game. He built Prevail Therapeutics into an Eli Lilly acquisition and co-founded Alector. His supporting cast is stacked: Xianglin Shi, Ph.D., CTO after a long run at Biogen; Eduardo Paredes, Ph.D., leading CMC with deep oligonucleotide expertise; Herve Rhinn, Ph.D., driving discovery; Laura D. Heckman, Ph.D., steering translation after Prevail and Spark; Lawrence Severt, M.D., Ph.D., bringing AbbVie clinical firepower; and Hong Jiang, M.S., anchoring analytical sciences after Biogen.
The board is equally loaded. Athena Countouriotis, M.D., chairs after scaling Turning Point and now leading Avenzo. Carl Gordon, Ph.D., CFA, the OrbiMed Midas List mainstay. Mona Ashiya, Ph.D., General Partner at OrbiMed and co-founder of Prevail. Franz Hefti, Ph.D., the neuroscience veteran with Merck stripes. Christian Jung, Ph.D., Partner at SV Health. Philip DeSouza, M.D., surgeon-investor with Newpath. And Thomas Cahill, M.D., Ph.D., Newpath founder. This is validation at the highest level.
The Series A will advance LTX-001 into clinical efficacy studies for schizophrenia, push LTX-002 into ALS trials, and expand a pipeline built on genetics, biomarkers, and real biology. But here’s the signal buried in the noise: conviction scales. When you align science that matters with investors who get it, you don’t just chase markets; you create them.
